Feng Chi Biotech Corp. (TPEX:6744)
Taiwan · Delayed Price · Currency is TWD 15.50
0.00 (0.00%)
Sep 11, 2026, 12:50 PM CST
Feng Chi Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 239 | 274 | 305 | 342 | 308 | 381 | |
Market Cap Growth | -23.27% | -10.10% | -10.81% | 11.00% | -19.19% | -16.10% |
Enterprise Value | 71 | 89 | 96 | 128 | 83 | 159 |
Last Close Price | 15.50 | 16.87 | 17.90 | 19.14 | 16.33 | 19.08 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.10 | 18.94 | 18.38 | 15.00 | 12.51 | 16.48 |
PS Ratio | 1.52 | 1.55 | 1.78 | 1.89 | 1.59 | 2.09 |
PB Ratio | 1.04 | 1.14 | 1.27 | 1.44 | 1.31 | 1.65 |
P/TBV Ratio | 1.04 | 1.14 | 1.27 | 1.44 | 1.31 | 1.65 |
P/FCF Ratio | 138.62 | - | 29.16 | 24.39 | 10.85 | 11.98 |
P/OCF Ratio | 98.64 | 84.71 | 12.17 | 22.18 | 10.81 | 11.58 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.45 | 0.50 | 0.56 | 0.71 | 0.43 | 0.87 |
EV/EBITDA Ratio | 3.62 | 3.84 | 4.25 | 4.48 | 2.72 | 4.88 |
EV/EBIT Ratio | 10.00 | 6.45 | 5.96 | 5.32 | 3.08 | 6.00 |
EV/FCF Ratio | 41.46 | - | 9.20 | 9.16 | 2.93 | 4.99 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.03 | 0.05 | 0.06 | 0.01 |
Debt / EBITDA Ratio | 0.21 | 0.21 | 0.32 | 0.34 | 0.40 | 0.07 |
Debt / FCF Ratio | 2.35 | - | 0.78 | 0.77 | 0.47 | 0.08 |
Net Debt / Equity Ratio | -0.73 | -0.72 | -0.83 | -0.86 | -0.94 | -0.99 |
Net Debt / EBITDA Ratio | -9.85 | -7.43 | -8.80 | -7.16 | -7.22 | -7.00 |
Net Debt / FCF Ratio | -97.16 | 17.65 | -19.03 | -14.63 | -7.80 | -7.15 |
Asset Turnover | 0.54 | 0.60 | 0.57 | 0.59 | 0.65 | 0.64 |
Inventory Turnover | 2.79 | 3.65 | 4.93 | 4.49 | 4.81 | 4.08 |
Quick Ratio | 3.83 | 4.28 | 4.16 | 4.21 | 4.01 | 4.32 |
Current Ratio | 4.48 | 5.14 | 4.60 | 4.66 | 4.47 | 4.74 |
Return on Equity (ROE) | 4.28% | 6.03% | 6.94% | 9.62% | 10.55% | 10.16% |
Return on Assets (ROA) | 1.52% | 2.95% | 3.36% | 4.96% | 5.69% | 5.79% |
Return on Invested Capital (ROIC) | 10.06% | 21.91% | 35.70% | 85.47% | 255.76% | 314.29% |
Return on Capital Employed (ROCE) | 3.10% | 5.70% | 6.60% | 9.80% | 11.00% | 11.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.15% | 5.28% | 5.44% | 6.67% | 7.99% | 6.07% |
FCF Yield | 0.72% | -3.57% | 3.43% | 4.10% | 9.22% | 8.35% |
Dividend Yield | 6.00% | 4.98% | 5.31% | 5.49% | 8.27% | 6.55% |
Payout Ratio | 147.70% | 101.08% | 97.45% | 91.22% | 78.21% | 76.55% |
Buyback Yield / Dilution | 0.06% | 0.08% | -0.02% | 0.07% | -0.08% | -0.01% |
Total Shareholder Return | 6.06% | 5.06% | 5.29% | 5.55% | 8.18% | 6.54% |